MXPA01002898A - Metodos de modulacion descendente de la respuesta inmune a proteinas terapeuticas. - Google Patents

Metodos de modulacion descendente de la respuesta inmune a proteinas terapeuticas.

Info

Publication number
MXPA01002898A
MXPA01002898A MXPA01002898A MXPA01002898A MXPA01002898A MX PA01002898 A MXPA01002898 A MX PA01002898A MX PA01002898 A MXPA01002898 A MX PA01002898A MX PA01002898 A MXPA01002898 A MX PA01002898A MX PA01002898 A MXPA01002898 A MX PA01002898A
Authority
MX
Mexico
Prior art keywords
agent
antibody
factor viii
cell
composition
Prior art date
Application number
MXPA01002898A
Other languages
English (en)
Spanish (es)
Inventor
Mary Collins
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of MXPA01002898A publication Critical patent/MXPA01002898A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA01002898A 1998-09-21 1999-09-21 Metodos de modulacion descendente de la respuesta inmune a proteinas terapeuticas. MXPA01002898A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
PCT/US1999/021991 WO2000016801A1 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Publications (1)

Publication Number Publication Date
MXPA01002898A true MXPA01002898A (es) 2002-06-04

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01002898A MXPA01002898A (es) 1998-09-21 1999-09-21 Metodos de modulacion descendente de la respuesta inmune a proteinas terapeuticas.

Country Status (21)

Country Link
EP (1) EP1115423A1 (zh)
JP (1) JP2002526455A (zh)
KR (1) KR20010085830A (zh)
CN (1) CN1331602A (zh)
AU (1) AU761206B2 (zh)
BR (1) BR9913991A (zh)
CA (1) CA2343916A1 (zh)
CZ (1) CZ20011021A3 (zh)
EA (1) EA005236B1 (zh)
HK (1) HK1039059A1 (zh)
HU (1) HUP0103960A3 (zh)
IL (1) IL142069A0 (zh)
LT (1) LT4920B (zh)
LV (1) LV12768B (zh)
MX (1) MXPA01002898A (zh)
NO (1) NO20011412L (zh)
NZ (1) NZ511034A (zh)
PL (1) PL346796A1 (zh)
SI (1) SI20626A (zh)
WO (1) WO2000016801A1 (zh)
ZA (1) ZA200103156B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
EP1289552B1 (en) * 2000-05-19 2006-03-29 The Center for Blood Research, INC. Methods for treating hemostatic disorders by soluble p-selectin
EP1636579A4 (en) * 2003-06-10 2011-10-05 Smiths Detection Inc SENSOR ASSEMBLY
GB201508024D0 (en) 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
CA1341174C (en) 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996005860A1 (en) * 1994-08-19 1996-02-29 Novo Nordisk A/S A method of treating a patient with a biologically active compound
JPH10507758A (ja) * 1994-10-19 1998-07-28 ジェネティック セラピー，インコーポレイテッド アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
EP1034001B1 (en) * 1997-06-20 2004-08-04 Biogen Idec MA Inc. Cd154 blockade therapy for therapeutic protein inhibitor syndrome
US8112896B2 (en) 2009-11-06 2012-02-14 Hexagon Metrology Ab Articulated arm

Also Published As

Publication number Publication date
LT4920B (lt) 2002-06-25
BR9913991A (pt) 2001-07-03
IL142069A0 (en) 2002-03-10
NZ511034A (en) 2004-03-26
HUP0103960A2 (hu) 2002-02-28
WO2000016801A9 (en) 2000-10-26
AU6057899A (en) 2000-04-10
WO2000016801A1 (en) 2000-03-30
LT2001045A (en) 2002-01-25
CA2343916A1 (en) 2000-03-30
HUP0103960A3 (en) 2003-09-29
EA200100385A1 (ru) 2001-10-22
HK1039059A1 (zh) 2002-04-12
LV12768A (en) 2001-12-20
KR20010085830A (ko) 2001-09-07
LV12768B (lv) 2002-06-20
CZ20011021A3 (cs) 2001-10-17
JP2002526455A (ja) 2002-08-20
SI20626A (sl) 2002-02-28
PL346796A1 (en) 2002-02-25
EA005236B1 (ru) 2004-12-30
NO20011412D0 (no) 2001-03-20
CN1331602A (zh) 2002-01-16
ZA200103156B (en) 2002-07-18
AU761206B2 (en) 2003-05-29
EP1115423A1 (en) 2001-07-18
NO20011412L (no) 2001-05-16

Similar Documents

Publication Publication Date Title
Lollar Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX
Qian et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia A
JP4052524B2 (ja) Ｔ細胞における抗原特異性アポトーシスの誘導のためのリガンド
US20020051784A1 (en) Methods for modulating T cell unresponsiveness
US20120269806A1 (en) Methods of inducing tolerance
Qian et al. Role of CD154 in the secondary immune response: the reduction of pre‐existing splenic germinal centers and anti‐factor VIII inhibitor titer
EP0474691B1 (en) Monoclonal antibodies for inducing tolerance
US20080095774A1 (en) Agents and Methods for Specifically Blocking CD28-Mediated Signaling
Miao et al. Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice
US20210340214A1 (en) Cd80 extracellular domain fc fusion protein dosing regimens
BG64436B1 (en) Cd154 blockade therapy for the treatment of protein inhibition syndrome
US20070092506A1 (en) Use of rapamycin and agents that inhibit B7 activity in immunomodulation
Fijnvandraat et al. Immunobiology of inhibitor development in hemophilia A
AU761206B2 (en) Methods of downmodulating the immune response to therapeutic proteins
US20030161827A1 (en) Therapies that improve graft survival
US20230023174A1 (en) Cd80 extracellular domain fc fusion protein regimens
US20020071839A1 (en) Use of a combination of agents that modulate B7 activity in inhibiting intestinal allograft rejection
Bril Factor VIII inhibitors in mild haemophilia A
Miao et al. Immunomodulation of transgene responses following naked DNA transfer
Chen et al. Immunological tolerance of human hepatocyte xenograft induced by adenovirus vector-mediated CTLA4Ig gene transfer
Qadura FVIII Immunity: early events and tolerance mechanisms to FVIII
Ahmiedat Induction of Transplantation Tolerance Using Monoclonal Antibodies to CD4: Experimental Studies Using a Rat Heterotopic Cardiac Allograft Model
Sasgary Characterization and analysis of FVIII-specific T cells in hemophilic mice treated with human factor VIII-development of new strategies for tolerance induction
AU3437902A (en) Methods for modulating T cell unresponsiveness
MXPA99010571A (en) Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection